This page shows the latest Donanemab news and features for those working in and with pharma, biotech and healthcare.
This meant many patients were able to stop treatment after six months, resulting in fewer than 100 patients receiving 12 months of donanemab. ... The company’s application was based on results from a phase 2 trial in which donanemab demonstrated
Reuters noted that analysts have observed Lilly’s increased spending on R&D “ahead of presenting data for its keenly watched donanemab drug for Alzheimer's disease as well as its
In a key secondary outcome, donanemab reduced brain amyloid levels versus baseline by 65.2% compared with 17.0% for Aduhelm at six months. ... Additionally, an exploratory outcome showed donanemab, but not Aduhelm, significantly reduced plasma P-tau217
The first is that Lilly has started a rolling submission to the US Food and Drug Administration (FDA) for accelerated approval of donanemab in early Alzheimer's disease. ... through 2030, bolstered by multiple pipeline readouts of its
In June, Eli Lilly received breakthrough therapy designation for its Alzheimer’s therapy, donanemab.
This includes the company’s potential drug for Alzheimer’s disease, donanemab, which received breakthrough therapy designation in June based on its phase 2 data. ... Importantly, this data links the mechanism of action of donanemab, plaque clearance,
More from news
Approximately 7 fully matching, plus 5 partially matching documents found.
Recently published study results for aducanumab and donanemab, both antibodies against amyloid, showed effects that indicated some improvement in cognition and daily function in patients with early Alzheimer’s. ... In the aforementioned aducanumab and
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...